# A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)

> **NCT01937871** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 909 (actual)

## Conditions studied

- Benign Prostate Hyperplasia
- Erectile Dysfunction

## Interventions

- **DRUG:** 5 mg Tadalafil
- **DRUG:** Placebo
- **DRUG:** 0.2 mg Tamsulosin

## Key facts

- **NCT ID:** NCT01937871
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 909 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937871, "A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01937871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*